WallStSmart

Stryker Corporation (SYK)vsTandem Diabetes Care Inc (TNDM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Stryker Corporation generates 2375% more annual revenue ($25.12B vs $1.01B). SYK leads profitability with a 12.9% profit margin vs -20.2%. SYK earns a higher WallStSmart Score of 65/100 (C+).

SYK

Buy

65

out of 100

Grade: C+

Growth: 8.0Profit: 7.5Value: 9.3Quality: 7.0
Piotroski: 3/9Altman Z: 2.18

TNDM

Avoid

27

out of 100

Grade: F

Growth: 4.0Profit: 2.5Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

SYKUndervalued (+16.8%)

Margin of Safety

+16.8%

Fair Value

$393.59

Current Price

$327.65

$65.94 discount

UndervaluedFair: $393.59Overvalued

Intrinsic value data unavailable for TNDM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

SYK4 strengths · Avg: 8.8/10
EPS GrowthGrowth
55.9%10/10

Earnings expanding 55.9% YoY

Market CapQuality
$125.72B9/10

Large-cap with strong market position

Operating MarginProfitability
27.2%8/10

Strong operational efficiency at 27.2%

Free Cash FlowQuality
$1.88B8/10

Generating 1.9B in free cash flow

TNDM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

SYK3 concerns · Avg: 3.7/10
PEG RatioValuation
1.604/10

Expensive relative to growth rate

P/E RatioValuation
39.1x4/10

Premium valuation, high expectations priced in

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

TNDM4 concerns · Avg: 3.5/10
Price/BookValuation
10.7x4/10

Trading at 10.7x book value

Revenue GrowthGrowth
2.7%4/10

2.7% revenue growth

Market CapQuality
$1.66B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
2.9%3/10

Operating margin of 2.9%

Comparative Analysis Report

WallStSmart Research

Bull Case : SYK

The strongest argument for SYK centers on EPS Growth, Market Cap, Operating Margin. Revenue growth of 11.4% demonstrates continued momentum.

Bull Case : TNDM

TNDM has a balanced fundamental profile.

Bear Case : SYK

The primary concerns for SYK are PEG Ratio, P/E Ratio, Piotroski F-Score.

Bear Case : TNDM

The primary concerns for TNDM are Price/Book, Revenue Growth, Market Cap. Debt-to-equity of 3.64 is elevated, increasing financial risk.

Key Dynamics to Monitor

SYK profiles as a value stock while TNDM is a turnaround play — different risk/reward profiles.

TNDM carries more volatility with a beta of 1.67 — expect wider price swings.

SYK is growing revenue faster at 11.4% — sustainability is the question.

SYK generates stronger free cash flow (1.9B), providing more financial flexibility.

Bottom Line

SYK scores higher overall (65/100 vs 27/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Stryker Corporation

HEALTHCARE · MEDICAL DEVICES · USA

Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as well as other medical device products used in a variety of medical specialties.

Visit Website →

Tandem Diabetes Care Inc

HEALTHCARE · MEDICAL DEVICES · USA

Tandem Diabetes Care, Inc., a medical device company, designs, develops, and markets various products for people with insulin-dependent diabetes in the United States. The company is headquartered in San Diego, California.

Visit Website →

Want to dig deeper into these stocks?